Das Mithilesh K, Gaitonde Rajdeep, Miller John M
Department of Medicine, Krannert Institute of Cardiology, Indiana University School of Medicine, 1800 North Capitol Avenue, Indianapolis, IN 46202, USA.
Curr Cardiol Rep. 2007 Sep;9(5):371-80. doi: 10.1007/BF02938364.
The implantable cardioverter defibrillator (ICD) is used for primary and secondary prophylaxis of sudden cardiac death in high-risk patients. Although several trials have demonstrated the superiority of ICD over standard medical therapy or antiarrhythmic medication in this population, a few trials have not shown survival benefit. This review examines the major ICD trials that provide the basis for current therapy in this rapidly changing and very important area of cardiology.
植入式心脏复律除颤器(ICD)用于高危患者心脏性猝死的一级和二级预防。尽管多项试验已证明ICD在该人群中优于标准药物治疗或抗心律失常药物,但也有一些试验未显示出生存获益。本综述审视了主要的ICD试验,这些试验为心脏病学这一快速变化且非常重要领域的当前治疗提供了依据。